US Markets

U.S. FDA okays wider use of GSK ovarian cancer drug

Credit: REUTERS/Loriene Perera

GlaxoSmithKline said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

Oct 23 (Reuters) - GlaxoSmithKline GSK.L said on Wednesday U.S. regulators approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca AZN.L.

The U.S. Food and Drug Administration approval is for the drug's use in advanced ovarian, fallopian tube, or primary peritoneal cancer patients who had undergone at least three prior chemotherapy regimens and whose disease had come back.

Zejula was the lead compound of U.S. cancer specialist Tesaro, which GSK acquired for $5.1 billion last year. Zejula brought in sales of 57 million pounds ($73.59 million) in the second quarter.

($1 = 0.7745 pounds)

(Reporting by Pushkala Aripaka and Manojna Maddipatla in Bengaluru)

((Pushkala.A@thomsonreuters.com; Twitter: @pushkala_a; within UK: +44 20 7542 1810, outside UK: +91 80 6749 6633;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest US Markets Videos

#TradeTalks: Traders See Plenty of Opportunity, but Should Investors Aggressively Buy the Dip?

Shawn Cruz, Manager, Trader Services at TD Ameritrade, joins Jill Malandrino on #TradeTalks to discuss whether or not investors should aggressively buy the dip.

1 day ago

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More